- Home
- ZIP vs FENC Comparison
ZIP vs FENC Comparison
Compare ZIP & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIP | FENC |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.9M | 266.4M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ZIP | FENC |
|---|---|---|
| Price | $2.44 | $6.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $3.88 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.2M | 222.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $448,952,000.00 | $44,642,000.00 |
| Revenue This Year | $1.00 | $69.68 |
| Revenue Next Year | $5.93 | $37.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.65 | $5.02 |
| 52 Week High | $6.55 | $9.92 |
Technical Indicators
Market Signals| Indicator | ZIP | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 42.14 |
| Support Level | $1.68 | $5.65 |
| Resistance Level | $2.59 | $8.09 |
| Average True Range (ATR) | 0.19 | 0.41 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 98.03 | 57.84 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace that connects job seekers and employers through an AI-powered platform. The company provides recruiting solutions that help employers identify and hire qualified candidates while enabling job seekers to discover relevant job opportunities through intelligent matching and recommendation tools.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.